Real-world (rw) treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic tx and avelumab 1L maintenance (1LM): Results from the IMPACT UC-III study.
| Publicado en: | Journal of Clinical Oncology Vol. 42; pp. 390 - 403 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2024 Supplement 10
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Descripción no disponible. |